Pseudomonal Diabetic Foot Infections: Vive la Différence?
- PMID: 35634135
- PMCID: PMC9130228
- DOI: 10.1016/j.mayocpiqo.2022.04.005
Pseudomonal Diabetic Foot Infections: Vive la Différence?
Abstract
Objective: To assess the outcomes of diabetic foot infections (DFIs) due to Pseudomonas aeruginosa.
Patients and methods: From April 24, 2013 to July 31, 2016, we analyzed data from patients prospectively enrolled in our clinical pathway of DFIs, comparing those with infection due to Pseudomonas with those without infection due to Pseudomonas.
Results: Overall, we assessed 1018 cases of DFIs: 392 with osteomyelitis and 626 with only soft tissue infections. The prevalence of P aeruginosa in deep wound cultures was 10% (104/1018); of the 1018 cultures, 22 were monomicrobial, 82 were polymicrobial, and 46 were with osteomyelitis. Overall, the patients were treated with a median of 1 surgical debridement and a total of 20 days of antibiotic therapy. In a comparison of crude groups, the proportion of clinical failures was significantly higher with Pseudomonas than with other pathogens (36/104 [35%] vs 218/914 [24%], respectively; P=.02). A multivariate analysis showed that pseudomonal DFIs did not recur more often than nonpseudomonal DFIs (hazard ratio, 1.0; 95% confidence interval, 0.6-1.7). Among the 104 cases of pseudomonal DFIs, there was no association between failure of treatment and the total duration of antibiotic therapy, duration of intravenous therapy, duration of combined antibiotic therapy with more than 1 agent, or duration of oral (fluoroquinolone) therapy. Among 15 cases of pseudomonal recurrence, 2 (13%) developed resistance to the antibiotic agent used for the index episode.
Conclusion: For DFIs caused by P aeruginosa, other than choosing an antibiotic agent that is active against the organism, it does not appear necessary to treat with a different therapeutic regimen compared with the treatment of nonpseudomonal DFIs. There is no difference!
Keywords: CI, confidence interval; DFI, diabetic foot infection; DFO, diabetic foot osteomyelitis; HR, hazard ratio; IDSA, Infectious Diseases Society of America; IQR, interquartile range; IWGDF, International Working Group on the Diabetic Foot.
© 2022 The Authors.
Similar articles
-
Remission in diabetic foot infections: Duration of antibiotic therapy and other possible associated factors.Diabetes Obes Metab. 2019 Feb;21(2):244-251. doi: 10.1111/dom.13507. Epub 2018 Sep 21. Diabetes Obes Metab. 2019. PMID: 30129109
-
Prevalence and Predictors of Pseudomonas aeruginosa Among Hospitalized Patients With Diabetic Foot Infections.Open Forum Infect Dis. 2022 Jun 17;9(7):ofac297. doi: 10.1093/ofid/ofac297. eCollection 2022 Jul. Open Forum Infect Dis. 2022. PMID: 35873292 Free PMC article.
-
Oral amoxicillin-clavulanate for treating diabetic foot infections.Diabetes Obes Metab. 2019 Jun;21(6):1483-1486. doi: 10.1111/dom.13651. Epub 2019 Mar 12. Diabetes Obes Metab. 2019. PMID: 30719838
-
A Comprehensive Review of the Pathogenesis, Diagnosis, and Management of Diabetic Foot Infections.Adv Skin Wound Care. 2021 Nov 1;34(11):574-581. doi: 10.1097/01.ASW.0000791876.10485.d4. Adv Skin Wound Care. 2021. PMID: 34669660 Review.
-
Management of diabetic foot infections in the light of recent literature and new international guidelines.Expert Rev Anti Infect Ther. 2020 Apr;18(4):293-305. doi: 10.1080/14787210.2020.1730177. Epub 2020 Feb 19. Expert Rev Anti Infect Ther. 2020. PMID: 32052672 Review.
Cited by
-
What's old is new again: Insights into diabetic foot microbiome.World J Diabetes. 2023 Jun 15;14(6):680-704. doi: 10.4239/wjd.v14.i6.680. World J Diabetes. 2023. PMID: 37383589 Free PMC article. Review.
-
Influence of Skin Commensals on Therapeutic Outcomes of Surgically Debrided Diabetic Foot Infections-A Large Retrospective Comparative Study.Antibiotics (Basel). 2023 Feb 3;12(2):316. doi: 10.3390/antibiotics12020316. Antibiotics (Basel). 2023. PMID: 36830227 Free PMC article.
-
Novel antimicrobial strategies for diabetic foot infections: addressing challenges and resistance.Acta Diabetol. 2025 Mar;62(3):303-321. doi: 10.1007/s00592-024-02438-3. Epub 2025 Jan 6. Acta Diabetol. 2025. PMID: 39760785 Review.
-
Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics.Cells. 2023 Jan 3;12(1):199. doi: 10.3390/cells12010199. Cells. 2023. PMID: 36611992 Free PMC article. Review.
-
Antibiotic Stewardship in the Management of Infected Diabetic Foot Ulcer Disease in Less Developed Countries.Endocrinol Diabetes Metab. 2024 Jul;7(4):e00503. doi: 10.1002/edm2.503. Endocrinol Diabetes Metab. 2024. PMID: 38924696 Free PMC article. Review.
References
-
- Uçkay I., Gariani K., Pataky Z., Lipsky B.A. Diabetic foot infections: state-of-the-art. Diabetes Obes Metab. 2014;16(4):305–316. - PubMed
-
- Uçkay I., Berli M., Sendi P., Lipsky B.A. Principles and practice of antibiotic stewardship in the management of diabetic foot infections. Curr Opin Infect Dis. 2019;32(2):95–101. - PubMed
-
- Gariani K., Lebowitz D., von Dach E., Kressmann B., Lipsky B.A., Uçkay I. Remission in diabetic foot infections: duration of antibiotic therapy and other possible associated factors. Diabetes Obes Metab. 2019;21(2):244–251. - PubMed
-
- Uçkay I., Kressmann B., Malacarne S., et al. A randomized, controlled study to investigate the efficacy and safety of a topical gentamicin-collagen sponge in combination with systemic antibiotic therapy in diabetic patients with a moderate or severe foot ulcer infection. BMC Infect Dis. 2018;18(1):1–9. - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous